Please login to the form below
CAR T therapy
This page shows the latest CAR T therapy news and features for those working in and with pharma, biotech and healthcare.
University of Strathclyde develops pre-clinical screening tool which could increase cancer test numbers by up to 50 times
The screening tool enables large-scale testing of the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, a treatment effective against many haematological cancers but one that presents ... Researchers at the University of
Latest news
-
Novartis announces promising five-year data for leukaemia treatment Kymriah
The data shows the potential of Kymriah as a cure, and as the only CAR T-cell therapy available for such patients who have previously had limited treatment options. ... The ELIANA trial was the first worldwide CAR T-cell therapy registration study,
-
EC approves Novartis’ Kymriah for advanced blood cancer
Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma. ... Novartis has announced that the European Commission (EC) has approved its CAR-T cell therapy, Kymriah (tisagenlecleucel), for the treatment of adult
-
Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
-
BMS and 2seventy bio move away from CAR-T programme
After forming a partnership to develop a multiple myeloma CAR-T cell therapy, Bristol Myers Squibb (BMS) and 2seventy bio have announced that the development plans have been scrapped, while sales ... Abecma, approved in March 2021 as the first BCMA CAR-T
-
bluebird bio splits to create new oncology firm 2seventy bio
Its portfolio includes a development and commercialisation deal with Bristol Myers Squibb for Abecma (idecabtagene vicleucel), its B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved by the Food ... The next six months looks set to be
More from news
Approximately 20 fully matching, plus 104 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point. ... A crucial challenge faced by cell and gene therapy developers is the necessity to balance clinical considerations with logistical ones such
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Examining three entirely different approaches to CAR-T therapy, it is possible to see just how much space there is for this exciting sector, therefore displaying the case for continued investment. ... Innovative CAR-T therapy demonstrates the depth of
-
Surviving cancer: a new era for patients
Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
In the precision medicine era, the line between products and services is blurred
In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have
-
The impossible launch
SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.
-
Understanding the evolving CAR-T market
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.
-
Precision paediatrics: Treating patients with CAR-T
Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.
-
Highlights in haematologic malignancy from ASH 2018
The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
